Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $227.45 ($1.2M) on 2026-05-01, disclosed to the SEC on 2026-05-04.
Scheduled sale ($1.2M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $227.45 | 600 | $136K | 11.8% |
| 2 | $228.75 | 932 | $213K | 18.4% |
| 3 | $229.71 | 98 | $23K | 1.9% |
| 4 | $230.87 | 370 | $85K | 7.4% |
| 5 | $232.04 | 780 | $181K | 15.6% |
| 6 | $232.92 | 1,420 |
| $331K |
| 28.6% |
| 7 | $234.02 | 800 | $187K | 16.2% |
| Total | $231.31 avg | 5,000 | $1.2M | 100% |
| Filing → |
| LGND | SELL | 2026-08-04 | $1.4M | — | Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |